Daiichi Sankyo seeks Japanese approval for Enhertu to treat patients with HER2 positive metastatic solid tumours: Tokyo Friday, April 25, 2025, 09:00 Hrs [IST] Daiichi Sankyo has ...

A program cochair said the agenda was designed to get attendees "out of their comfort zone." The Amercian Association for ...

On March 28, the FDA approved Imfinzi for use in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by single-agent Imfinzi as adjuvant treatment after radical cystectomy, ...

In the Phase III SELECT-GCA trial, Rinvoq (upadacitinib) 15 mg with a 26-week glucocorticoid taper significantly improved ...

EAGLE-1 trial data shows gepotidacin’s potential in treating gonorrhoea, for which no new antibiotics have been approved ...

The PFS benefit with T-DXd was observed across all prespecified patient subgroups. Overall survival (OS) data were not mature ...

AstraZeneca (AZ) and Daiichi Sankyo have shared positive results from a late-stage study of their antibody drug conjugate (ADC) Enhertu (trastuzumab deruxtecan) in patients with HER2-positive ...

Astra said a trial of its Enhertu treatment showed the drug demonstrated a 'highly statistically significant' improvement on ...

I received my recent scan results.  After previously requesting to see my oncologist and being assured I would, I was led into a room ...

Naloxone Now Available Directly Through CalRx For $24: California residents can buy the overdose reversal nasal spray naloxone directly from the state through the CalRx program, Gov. Gavin Newsom ...

Enhertu (fam-trastuzumab deruxtecan-nxki) is currently indicated as a second-line therapy for HER2-positive metastatic breast cancer.

The findings published Monday analyzed data from 2001 through 2022. However, incidence rates among women have been rising. Separately, a survey shows women are reluctant to have cancer screening ...